<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>XTANDI- enzalutamide capsule </strong><br>Astellas Pharma US, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use XTANDI<span class="Sup">®</span> safely and effectively. See full prescribing information for XTANDI. <br><br>XTANDI<span class="Sup">®</span> (enzalutamide) capsules for oral use<br>Initial U.S. Approval: 2012</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Indications and Usage (<a href="#i4i_indications_id_b3546dca-c518-41f3-83bc-b177f0de509f">1</a>)                                  09/2014<br>Contraindications (<a href="#i4i_contraindications_id_ab654d32-39f5-45ce-bcfe-90f16a6409a6">4</a>)                                         09/2014<br>Warnings and Precautions (<a href="#i4i_section_id_2353d0ee-3120-4e4e-aef8-99f54b115f59">5.1</a>)                         09/2014<br>Warnings and Precautions (<a href="#ID_3cfc7ec2-f521-4f08-a3a2-af6ee3371d45">5.2</a>)                         08/2015 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer. (<a href="#i4i_indications_id_b3546dca-c518-41f3-83bc-b177f0de509f">1</a>)   </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">XTANDI 160 mg (four 40 mg capsules) administered orally once daily. Swallow capsules whole. XTANDI can be taken with or without food. (<a href="#i4i_section_id_137b3b01-ca8a-471c-92f7-b3cf11c3dc53">2.1</a>)   </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsule 40 mg (<a href="#i4i_dosage_form_strength_id_a293ee18-6386-4714-90e3-3798c280ac67">3</a>)   </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Pregnancy (<a href="#i4i_contraindications_id_ab654d32-39f5-45ce-bcfe-90f16a6409a6">4</a>, <a href="#i4i_pregnancy_id_1dad9baf-9305-451e-83ac-2f015cf2978f">8.1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> occurred in 0.9% of patients receiving XTANDI who previously received docetaxel and in 0.1% of patients who were chemotherapy-naive. There is no clinical trial experience with XTANDI in patients who have had a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. Permanently discontinue XTANDI in patients who develop a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> during treatment. (<a href="#i4i_section_id_2353d0ee-3120-4e4e-aef8-99f54b115f59">5.1</a>) </dd>
<dt>•</dt>
<dd>Posterior reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> syndrome (PRES): Discontinue XTANDI. (<a href="#ID_3cfc7ec2-f521-4f08-a3a2-af6ee3371d45">5.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (≥ 10%) are <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. (<a href="#i4i_section_id_09ca00de-6699-4d04-988b-d0562e10ed6e">6.1</a>)<br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Avoid strong CYP2C8 inhibitors, as they can increase the plasma exposure to XTANDI. If co-administration is necessary, reduce the dose of XTANDI. (<a href="#i4i_section_id_67ff910f-5662-4741-8c5a-08db7cef628b">2.2</a>, <a href="#i4i_section_id_d0a04c0b-f728-4f4a-982b-74621844660a">7.1</a>) </dd>
<dt>•</dt>
<dd>Avoid strong or moderate CYP3A4 or CYP2C8 inducers as they can alter the plasma exposure to XTANDI. (<a href="#i4i_section_id_d0a04c0b-f728-4f4a-982b-74621844660a">7.1</a>, <a href="#i4i_section_id_06eda248-5f46-43b7-8ed5-426f909644dc">7.2</a>)</dd>
<dt>•</dt>
<dd>Avoid CYP3A4, CYP2C9 and CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the plasma exposures of these drugs. If XTANDI is co-administered with warfarin (CYP2C9 substrate), conduct additional INR monitoring. (<a href="#i4i_section_id_4166cda9-55e6-4c73-a1de-da77f29e3fc0">7.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dose Modifications</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Posterior Reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> Syndrome (PRES) </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Post-Marketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs that Inhibit or Induce CYP2C8</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs that Inhibit or Induce CYP3A4</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Effect of XTANDI on Drug Metabolizing Enzymes</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.6 Cardiac Electrophysiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_b3546dca-c518-41f3-83bc-b177f0de509f"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">XTANDI<span class="Sup">®</span> is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_6b2ad128-3683-4af7-aa7f-f56e6d0c6e30"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_137b3b01-ca8a-471c-92f7-b3cf11c3dc53"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information</h2>
<p class="First">The recommended dose of XTANDI is 160 mg (four 40 mg capsules) administered orally once daily. XTANDI can be taken with or without food <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0">12.3</a>)]</span>. Swallow capsules whole. Do not chew, dissolve, or open the capsules.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67ff910f-5662-4741-8c5a-08db7cef628b"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dose Modifications</h2>
<p class="First">If a patient experiences a ≥ Grade 3 toxicity or an intolerable side effect, withhold dosing for one week or until symptoms improve to ≤ Grade 2, then resume at the same or a reduced dose (120 mg or 80 mg), if warranted.</p>
<p><span class="Bold"><span class="Underline">Concomitant Strong CYP2C8 Inhibitors</span></span></p>
<p>The concomitant use of strong CYP2C8 inhibitors should be avoided if possible. If patients must be co-administered a strong CYP2C8 inhibitor, reduce the XTANDI dose to 80 mg once daily. If co-administration of the strong inhibitor is discontinued, the XTANDI dose should be returned to the dose used prior to initiation of the strong CYP2C8 inhibitor <span class="Italics">[see <a href="#i4i_interactions_id_95e7e5ea-8a64-4b94-be6e-b07a80ef3c01">Drug Interactions</a> (<a href="#i4i_section_id_d0a04c0b-f728-4f4a-982b-74621844660a">7.1</a>) and <a href="#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_a293ee18-6386-4714-90e3-3798c280ac67"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">XTANDI 40 mg capsules are white to off-white oblong soft gelatin capsules imprinted in black ink with ENZ.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_ab654d32-39f5-45ce-bcfe-90f16a6409a6"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Pregnancy</span></span><br><span class="XmChange">XTANDI can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. XTANDI is not indicated for use in women. XTANDI is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus and the potential risk for pregnancy loss <span class="Italics">[see <a href="#i4i_specific_populations_id_9f194aa3-8255-45d3-81b1-4feca47574c7">Use in Specific Populations</a> (<a href="#i4i_pregnancy_id_1dad9baf-9305-451e-83ac-2f015cf2978f">8.1</a>)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_f3fadd5f-4ed3-4b88-9a17-c83dfcde308d"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2353d0ee-3120-4e4e-aef8-99f54b115f59"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In Study 1, which enrolled patients who previously received docetaxel, 7 of 800 (0.9%) patients treated with XTANDI experienced a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and no patients treated with placebo experienced a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> occurred from 31 to 603 days after initiation of XTANDI. In Study 2, 1 of 871 (0.1%) chemotherapy-naive patients treated with XTANDI and 1 of 844 (0.1%) patients treated with placebo experienced a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. Patients experiencing <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> were permanently discontinued from therapy and all <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> events resolved. There is no clinical trial experience re-administering XTANDI to patients who experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Limited safety data are available in patients with predisposing factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> because these patients were generally excluded from the trials.  These exclusion criteria included a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, underlying brain injury with <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, transient ischemic attack within the past 12 months, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="378087" conceptname="Secondary malignant neoplasm of brain and spinal cord">brain metastases</span>, and brain <span class="product-label-link" type="condition" conceptid="4075418" conceptname="Arteriovenous malformation">arteriovenous malformation</span>. Study 1 excluded the use of concomitant medications that may lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, whereas Study 2 permitted the use of these medications. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Because of the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> associated with XTANDI use, patients should be advised of the risk of engaging in any activity where sudden <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> could cause serious harm to themselves or others. Permanently discontinue XTANDI in patients who develop a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> during treatment. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3cfc7ec2-f521-4f08-a3a2-af6ee3371d45"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Posterior Reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> Syndrome (PRES) </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">There have been reports of posterior reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> syndrome (PRES) in patients receiving XTANDI <span class="Italics">[see <a href="#i4i_adverse_effects_id_f897588f-abce-492a-b0fd-4832a0aad3f2">Adverse Reactions</a> (<a href="#ID_b5f4213f-8904-4ab5-ade3-cef16ad94cc0">6.2</a>)]</span>. PRES is a neurological disorder which can present with rapidly evolving symptoms including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, and other visual and neurological disturbances, with or without associated <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinue XTANDI in patients who develop PRES.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_f897588f-abce-492a-b0fd-4832a0aad3f2"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following is discussed in more detail in other sections of the labeling:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> <span class="Italics">[see <a href="#i4i_warnings_precautions_id_f3fadd5f-4ed3-4b88-9a17-c83dfcde308d">Warnings and Precautions</a> (<a href="#i4i_section_id_2353d0ee-3120-4e4e-aef8-99f54b115f59">5.1</a>)]</span>
</dd>
<dt>•</dt>
<dd>Posterior Reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> Syndrome (PRES) <span class="Italics">[see <a href="#i4i_warnings_precautions_id_f3fadd5f-4ed3-4b88-9a17-c83dfcde308d">Warnings and Precautions</a> (<a href="#ID_3cfc7ec2-f521-4f08-a3a2-af6ee3371d45">5.2</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_09ca00de-6699-4d04-988b-d0562e10ed6e"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Two randomized clinical trials enrolled patients with metastatic prostate cancer that has progressed on androgen deprivation therapy (GnRH therapy or bilateral orchiectomy), a disease setting that is also defined as metastatic CRPC. In both studies, patients received XTANDI 160 mg orally once daily in the active treatment arm or placebo in the control arm. All patients continued androgen deprivation therapy. Patients were allowed, but not required, to take glucocorticoids.</p>
<p>The most common adverse reactions (≥ 10%) that occurred more commonly (≥ 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. </p>
<p><span class="Bold">Study 1: Metastatic Castration-Resistant Prostate Cancer Following Chemotherapy </span></p>
<p>Study 1 enrolled 1199 patients with metastatic CRPC who had previously received docetaxel. The median duration of treatment was 8.3 months with XTANDI and 3.0 months with placebo. During the trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids.  </p>
<p>Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients. Discontinuations due to adverse events were reported for 16% of XTANDI-treated patients and 18% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients. <a href="#_Ref381866877">Table 1</a> shows adverse reactions reported in Study 1 that occurred at a ≥ 2% higher frequency in the XTANDI arm compared to the placebo arm.</p>
<a name="_Ref381866877"></a><table width="100%">
<caption><span>Table 1. Adverse Reactions in Study 1</span></caption>
<col width="26%">
<col width="26%">
<col width="26%">
<col width="11%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">XTANDI</span></p>
<p><span class="Bold">N = 800</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N = 399</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Grade 1-4<span class="Sup">a</span></span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Grade 3-4</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Grade 1-4</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Grade 3-4</span></p>
<p><span class="Bold">(%)</span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">General Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Asthenic Conditions<span class="Sup">b</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">50.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">44.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">15.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">13.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.8</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Musculoskeletal And <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">26.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">24.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">20.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">17.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal Pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">15.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscular Weakness</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Musculoskeletal Stiffness</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">21.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">17.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flush</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">20.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.3</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12.1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><span class="Sup">c</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">Spinal Cord Compression</span> <br>    and <span class="product-label-link" type="condition" conceptid="4102342" conceptname="Cauda equina syndrome">Cauda Equina Syndrome</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">Mental Impairment</span> Disorders<span class="Sup">d</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> And <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Upper Respiratory Tract <br>    <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><span class="Sup">e</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10.9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Lower Respiratory Tract And <br>    <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">Lung Infection</span><span class="Sup">f</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.3</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Psychiatric Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Renal And Urinary Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6.9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Pollakiuria</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> And Procedural Complications</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Non-pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Skin And Subcutaneous Tissue Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry Skin</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="5" valign="top">
<p class="First">a    CTCAE v4</p>
<p>b    Includes <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.</p>
<p>c    Includes <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p>d    Includes <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="40480615" conceptname="Cognitive disorder">cognitive disorder</span>, and <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>.</p>
<p>e    Includes <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>.</p>
<p>f    Includes <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, and <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">lung infection</span>.</p>
</td></tr>
</tbody>
</table>
<p><span class="Bold">Study 2: Chemotherapy-naive Metastatic Castration-Resistant Prostate Cancer</span></p>
<p>Study 2 enrolled 1717 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 1715 received at least one dose of study drug. The median duration of treatment was 17.5 months with XTANDI and 4.6 months with placebo. Grade 3-4 adverse reactions were reported in 44% of XTANDI-treated patients and 37% of placebo-treated patients. Discontinuations due to adverse events were reported for 6% of XTANDI-treated patients and 6% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>/<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, which occurred in 1% of patients on each treatment arm. <a href="#_RefTable2">Table 2</a> includes adverse reactions reported in Study 2 that occurred at a ≥ 2% higher frequency in the XTANDI arm compared to the placebo arm. </p>
<a name="_RefTable2"></a><table cellpadding="0pt" width="100%">
<caption><span>Table 2. Adverse Reactions in Study 2</span></caption>
<col width="27%">
<col width="26%">
<col width="25%">
<col width="11%">
<col width="11%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom"></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">XTANDI</span><br><span class="Bold">N = 871</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">N = 844</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Grade 1-4<span class="Sup">a</span></span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Grade 3-4</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Grade 1-4</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Grade 3-4</span><br><span class="Bold">(%)</span>
</th>
</tr>
</thead>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="5" valign="top"><p class="First"><span class="Bold">General Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Asthenic Conditions<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">46.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">33.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Musculoskeletal And <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">28.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">22.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">21.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">23.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">17.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flush</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">18.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.3</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><span class="Sup">c</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">Mental Impairment</span> Disorders<span class="Sup">d</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory Disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span><span class="Sup">e</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">11.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.6</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> And <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Upper Respiratory Tract <br>    <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><span class="Sup">f</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Lower Respiratory Tract And <br>    <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">Lung Infection</span><span class="Sup">g</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Psychiatric Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Renal And Urinary Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.3</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> And Procedural Complications</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    Non-<span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">Pathological Fracture</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Metabolism and Nutrition Disorders</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">18.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.7</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Investigations</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decreased</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.2</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast disorders</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.0</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="5" valign="top">
<p class="First">a    CTCAE v4</p>
<p>b    Includes <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.                                                                                                        </p>
<p>c    Includes <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p>d    Includes <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="40480615" conceptname="Cognitive disorder">cognitive disorder</span>, and <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>.</p>
<p>e    Includes <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4263848" conceptname="Dyspnea on exertion">exertional dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> at rest.</p>
<p>f    Includes <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>.</p>
<p>g    Includes <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, and <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">lung infection</span>.</p>
</td></tr>
</tbody>
</table>
<p><span class="Bold">Laboratory Abnormalities </span><br>In the two randomized clinical trials, Grade 1-4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4). The incidence of Grade 1-4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was 6% of patients treated with XTANDI (0.3% Grade 3-4) and 5% of patients treated with placebo (0.5% Grade 3-4). Grade 1-4 elevations in ALT occurred in 10% of patients treated with XTANDI (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of patients treated with XTANDI (0.1% Grade 3-4) and 2% of patients treated with placebo (no Grade 3-4).  </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span><br>In Study 1, 1% of patients treated with XTANDI compared to 0.3% of patients treated with placebo died from <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>.   In Study 2, 1 patient in each treatment group (0.1%) had an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falls</span> and <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span>-related Injuries</span><br>In the two randomized clinical trials, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> including <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>-related injuries, occurred in 9% of patients treated with XTANDI compared to 4% of patients treated with placebo. <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falls</span> were not associated with <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span>-related injuries were more severe in patients treated with XTANDI and included non-pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, joint injuries, and <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span><br>In the two randomized trials, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> was reported in 11% of patients receiving XTANDI and 4% of patients receiving placebo. No patients experienced <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>. Medical history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> was balanced between arms. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> led to study discontinuation in &lt; 1% of patients in each arm.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b5f4213f-8904-4ab5-ade3-cef16ad94cc0"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Post-Marketing Experience </h2>
<p class="First">The following additional adverse reactions have been identified during post approval use of XTANDI. Because these reactions were  reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Neurological Disorders</span>: posterior reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> syndrome (PRES)</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_95e7e5ea-8a64-4b94-be6e-b07a80ef3c01"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d0a04c0b-f728-4f4a-982b-74621844660a"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs that Inhibit or Induce CYP2C8</h2>
<p class="First">Co-administration of a strong CYP2C8 inhibitor (gemfibrozil) increased the composite area under the plasma concentration-time curve (AUC) of enzalutamide plus N-desmethyl enzalutamide by 2.2-fold in healthy volunteers. Co‑administration of XTANDI with strong CYP2C8 inhibitors should be avoided if possible. If co-administration of XTANDI with a strong CYP2C8 inhibitor cannot be avoided, reduce the dose of XTANDI <span class="Italics">[see <a href="#i4i_dosage_admin_id_6b2ad128-3683-4af7-aa7f-f56e6d0c6e30">Dosage and Administration</a> (<a href="#i4i_section_id_67ff910f-5662-4741-8c5a-08db7cef628b">2.2</a>) and <a href="#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0">12.3</a>)].</span></p>
<p>The effects of CYP2C8 inducers on the pharmacokinetics of enzalutamide have not been evaluated <span class="Italics">in vivo</span>. Co-administration of XTANDI with strong or moderate CYP2C8 inducers (e.g., rifampin) may alter the plasma exposure of XTANDI and should be avoided if possible. Selection of a concomitant medication with no or minimal CYP2C8 induction potential is recommended <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_06eda248-5f46-43b7-8ed5-426f909644dc"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs that Inhibit or Induce CYP3A4</h2>
<p class="First">Co-administration of a strong CYP3A4 inhibitor (itraconazole) increased the composite AUC of enzalutamide plus N-desmethyl enzalutamide by 1.3-fold in healthy volunteers <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0">12.3</a>)].</span></p>
<p>The effects of CYP3A4 inducers on the pharmacokinetics of enzalutamide have not been evaluated <span class="Italics">in vivo</span>. Co-administration of XTANDI with strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine) may decrease the plasma exposure of XTANDI and should be avoided if possible. Selection of a concomitant medication with no or minimal CYP3A4 induction potential is recommended. Moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, nafcillin) and St. John’s Wort may also reduce the plasma exposure of XTANDI and should be avoided if possible <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4166cda9-55e6-4c73-a1de-da77f29e3fc0"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Effect of XTANDI on Drug Metabolizing Enzymes</h2>
<p class="First">Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer in humans. At steady state, XTANDI reduced the plasma exposure to midazolam (CYP3A4 substrate), warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate). Concomitant use of XTANDI with narrow therapeutic index drugs that are metabolized by CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin) and CYP2C19 (e.g., S-mephenytoin) should be avoided, as enzalutamide may decrease their exposure. If co-administration with warfarin cannot be avoided, conduct additional INR monitoring <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0">12.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_9f194aa3-8255-45d3-81b1-4feca47574c7"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_1dad9baf-9305-451e-83ac-2f015cf2978f"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category X </span><span class="Italics">[see <a href="#i4i_contraindications_id_ab654d32-39f5-45ce-bcfe-90f16a6409a6">Contraindications</a> (<a href="#i4i_contraindications_id_ab654d32-39f5-45ce-bcfe-90f16a6409a6">4</a>)]</span>.</p>
<p><span class="Italics">Risk Summary</span><br>XTANDI can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. While there are no human data on the use of XTANDI in pregnancy and XTANDI is not indicated for use in women, it is important to know that maternal use of an androgen receptor inhibitor could affect development of the fetus. Enzalutamide caused embryo-fetal toxicity in mice at exposures that were lower than in patients receiving the recommended dose. XTANDI is contraindicated in women who are or may become pregnant while receiving the drug. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus and the potential risk for pregnancy loss. Advise females of reproductive potential to avoid becoming pregnant during treatment with XTANDI.</p>
<p><span class="Italics">Animal Data</span><br>In an embryo-fetal developmental toxicity study in mice, enzalutamide caused developmental toxicity when administered at oral doses of 10 or 30 mg/kg/day throughout the period of organogenesis (gestational days 6-15). Findings included embryo-fetal lethality (increased post-implantation loss and resorptions) and decreased anogenital distance at ≥ 10 mg/kg/day, and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> and absent palatine bone at 30 mg/kg/day. Doses of 30 mg/kg/day caused maternal toxicity. The doses tested in mice (1, 10 and 30 mg/kg/day) resulted in systemic exposures (AUC) approximately 0.04, 0.4 and 1.1 times, respectively, the exposures in patients. Enzalutamide did not cause developmental toxicity in rabbits when administered throughout the period of organogenesis (gestational days 6-18) at dose levels up to 10 mg/kg/day (approximately 0.4 times the exposures in patients based on AUC).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_ab6e0009-d786-40f9-9cec-da80ccf41b0d"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">XTANDI is not indicated for use in women. It is not known if enzalutamide is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from XTANDI, a decision should be made to either discontinue nursing, or discontinue the drug taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_26c6b856-bacd-4952-bc60-cafd044355de"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of XTANDI in pediatric patients have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_bffd5750-c0fa-47ee-a9b1-7b56e7e301f1"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of 1671 patients who received XTANDI in the two randomized clinical trials, 75% were 65 and over, while 31% were 75 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_76350dd5-5bd3-48f0-a3c8-9c93ed78a572"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">A dedicated <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> trial for XTANDI has not been conducted. Based on the population pharmacokinetic analysis using data from clinical trials in patients with metastatic CRPC and healthy volunteers, no significant difference in enzalutamide clearance was observed in patients with pre-existing mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (30 mL/min ≤ creatinine clearance [CrCL] ≤ 89 mL/min) compared to patients and volunteers with baseline normal renal function (CrCL ≥ 90 mL/min). No initial dosage adjustment is necessary for patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCL &lt; 30 mL/min) and end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> have not been assessed <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cd0bc690-0998-428f-8463-1a21b2cb2c51"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">A dedicated <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> trial compared the composite systemic exposure of enzalutamide plus N-desmethyl enzalutamide in volunteers with baseline mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class A and B, respectively) versus healthy controls with normal hepatic function. The composite AUC of enzalutamide plus N-desmethyl enzalutamide was similar in volunteers with mild or moderate baseline <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to volunteers with normal hepatic function. No initial dosage adjustment is necessary for patients with baseline mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Baseline severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) has not been assessed <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_5a20096e-8725-4922-979d-66b52fb6f53e"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, stop treatment with XTANDI and initiate general supportive measures taking into consideration the half-life of 5.8 days. In a dose escalation study, no <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were reported at <span class="Underline">&lt;</span> 240 mg daily, whereas 3 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were reported, 1 each at 360 mg, 480 mg, and 600 mg daily. Patients may be at increased risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_19b4fdbd-4453-411a-b18c-234a57b1870c"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Enzalutamide is an androgen receptor inhibitor. The chemical name is 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-<span class="Italics">N</span>-methylbenzamide. </p>
<p>The molecular weight is 464.44 and molecular formula is C<span class="Sub">21</span>H<span class="Sub">16</span>F<span class="Sub">4</span>N<span class="Sub">4</span>O<span class="Sub">2</span>S. The structural formula is:</p>
<div class="Figure">
<a name="id449594699"></a><img alt="Structural formula of Enzalutamide" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf&amp;name=image-02.jpg">
</div>
<p>Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. </p>
<p>XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_df96fa8e-40da-499c-9b30-bf4ba2607d60"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_1cf486bb-b38a-4fdb-999b-1b2dc2ef7f2b"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors and inhibit androgen receptor nuclear translocation and interaction with DNA. A major metabolite, N-desmethyl enzalutamide, exhibited similar <span class="Italics">in vitro </span>activity to enzalutamide. Enzalutamide decreased proliferation and induced <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span> of prostate cancer cells <span class="Italics">in vitro</span>, and decreased tumor volume in a mouse prostate cancer xenograft model.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_ce3237da-0bda-41a4-aeaa-09489ee3d6c0"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of enzalutamide and its major active metabolite (N-desmethyl enzalutamide) were evaluated in patients with metastatic CRPC and healthy male volunteers. The plasma enzalutamide pharmacokinetics are adequately described by a linear two-compartment model with first-order absorption. <br><br><span class="Bold">Absorption</span><br>Following oral administration (XTANDI 160 mg daily) in patients with metastatic CRPC, the median time to reach maximum plasma enzalutamide concentrations (C<span class="Sub">max</span>) is 1 hour (range 0.5 to 3 hours). At steady state, the plasma mean C<span class="Sub">max</span> values for enzalutamide and N-desmethyl enzalutamide are 16.6 μg/mL (23% CV) and 12.7 μg/mL (30% CV), respectively, and the plasma mean predose trough values are 11.4 μg/mL (26% CV) and 13.0 μg/mL (30% CV), respectively.</p>
<p>With the daily dosing regimen, enzalutamide steady state is achieved by Day 28, and enzalutamide accumulates approximately 8.3-fold relative to a single dose. Daily fluctuations in enzalutamide plasma concentrations are low (mean peak-to-trough ratio of 1.25). At steady state, enzalutamide showed approximately dose proportional pharmacokinetics over the daily dose range of 30 to 360 mg. </p>
<p>A single 160 mg oral dose of XTANDI was administered to healthy volunteers with a high-fat meal or in the fasted condition. A high-fat meal did not alter the AUC to enzalutamide or N-desmethyl enzalutamide. The results are summarized in Figure 1. <br><br><span class="Bold">Distribution and Protein Binding</span><br>The mean apparent volume of distribution (V/F) of enzalutamide in patients after a single oral dose is 110 L (29% CV). </p>
<p>Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. N-desmethyl enzalutamide is 95% bound to plasma proteins. <span class="Italics">In vitro</span>, there was no protein binding displacement between enzalutamide and other highly protein bound drugs (warfarin, ibuprofen, and salicylic acid) at clinically relevant concentrations.<br><br><span class="Bold">Metabolism  </span><br>Following single oral administration of <span class="Sup">14</span>C-enzalutamide 160 mg, plasma samples were analyzed for enzalutamide and its metabolites up to 77 days post dose. Enzalutamide, N-desmethyl enzalutamide, and a major inactive carboxylic acid metabolite accounted for 88% of the <span class="Sup">14</span>C-radioactivity in plasma, representing 30%, 49%, and 10%, respectively, of the total <span class="Sup">14</span>C-AUC<span class="Sub">0-inf</span>.</p>
<p><span class="Italics">In vitro</span>, human CYP2C8 and CYP3A4 are responsible for the metabolism of enzalutamide. Based on <span class="Italics">in vivo</span> and <span class="Italics">in vitro</span> data, CYP2C8 is primarily responsible for the formation of the active metabolite (N-desmethyl enzalutamide).</p>
<p><span class="Italics">In vitro</span>, N-desmethyl enzalutamide is not a substrate of human CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5.<br><br><span class="Bold">Elimination </span><br>Enzalutamide is primarily eliminated by hepatic metabolism. Following single oral administration of <span class="Sup">14</span>C-enzalutamide 160 mg, 85% of the radioactivity is recovered by 77 days post dose: 71% is recovered in urine (including only trace amounts of enzalutamide and N-desmethyl enzalutamide), and 14% is recovered in feces (0.4% of dose as unchanged enzalutamide and 1% as N-desmethyl enzalutamide). </p>
<p>The mean apparent clearance (CL/F) of enzalutamide in patients after a single oral dose is 0.56 L/h (range 0.33 to 1.02 L/h). </p>
<p>The mean terminal half-life (t<span class="Sub">1/2</span>) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t<span class="Sub">1/2</span> for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.<br><br><span class="Bold">Pharmacokinetics in Special Populations</span><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>: <br>A population pharmacokinetic analysis (based on pre-existing renal function) was carried out with data from 59 healthy male volunteers and 926 patients with metastatic CRPC enrolled in clinical trials, including 512 with normal renal function (CrCL ≥ 90 mL/min), 332 with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCL 60 to &lt; 90 mL/min), 88 with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCL 30 to &lt; 60 mL/min), and 1 with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCL &lt; 30 mL/min). The apparent clearance of enzalutamide was similar in patients with pre-existing mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCL 30 to &lt; 90 mL/min) compared to patients and volunteers with normal renal function. The potential effect of severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on enzalutamide pharmacokinetics cannot be determined as clinical and pharmacokinetic data are available from only one patient <span class="Italics">[see <a href="#i4i_specific_populations_id_9f194aa3-8255-45d3-81b1-4feca47574c7">Use in Specific Populations</a> (<a href="#i4i_section_id_76350dd5-5bd3-48f0-a3c8-9c93ed78a572">8.6</a>)]</span>. <br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: <br>The plasma pharmacokinetics of enzalutamide and N-desmethyl enzalutamide were examined in volunteers with normal hepatic function (N = 16) and with pre-existing mild (N = 8, Child-Pugh Class A) or moderate (N = 8, Child-Pugh B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. XTANDI was administered as a single 160 mg dose. The composite AUC of enzalutamide plus N-desmethyl enzalutamide was similar in volunteers with mild or moderate baseline <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to volunteers with normal hepatic function. The results are summarized in Figure 1. Clinical and pharmacokinetic data are not available for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) <span class="Italics">[see <a href="#i4i_specific_populations_id_9f194aa3-8255-45d3-81b1-4feca47574c7">Use in Specific Populations</a> (<a href="#i4i_section_id_cd0bc690-0998-428f-8463-1a21b2cb2c51">8.7</a>)]</span>.<br><br><span class="Underline">Body Weight and Age:</span><br>Population pharmacokinetic analyses showed that weight (range: 46 to 163 kg) and age (range: 41 to 92 yr) do not have a clinically meaningful influence on the exposure to enzalutamide.<br><br><span class="Underline">Gender</span>: <br>The effect of gender on the pharmacokinetics of enzalutamide has not been evaluated.<br><br><span class="Underline">Race</span>: <br>The majority of XTANDI-treated patients in the randomized clinical trials were Caucasian (85%). Based on pharmacokinetic data from a study in Japanese patients with prostate cancer, there were no clinically relevant differences in exposure between Japanese and Caucasians. There are insufficient data to evaluate potential differences in the pharmacokinetics of enzalutamide in other races.  <br><br><span class="Bold">Drug Interactions</span></p>
<p><span class="Underline">Effect of Other Drugs on XTANDI:</span><br>In a drug-drug interaction trial in healthy volunteers, a single 160 mg oral dose of XTANDI was administered alone or after multiple oral doses of gemfibrozil (strong CYP2C8 inhibitor). Gemfibrozil increased the AUC<span class="Sub">0-inf</span> of enzalutamide plus N-desmethyl enzalutamide by 2.2-fold with minimal effect on C<span class="Sub">max</span>. The results are summarized in Figure 1 <span class="Italics">[see <a href="#i4i_dosage_admin_id_6b2ad128-3683-4af7-aa7f-f56e6d0c6e30">Dosage and Administration</a> (<a href="#i4i_section_id_67ff910f-5662-4741-8c5a-08db7cef628b">2.2</a>) and <a href="#i4i_interactions_id_95e7e5ea-8a64-4b94-be6e-b07a80ef3c01">Drug Interactions</a> (<a href="#i4i_section_id_d0a04c0b-f728-4f4a-982b-74621844660a">7.1</a>)].</span></p>
<p>In a drug-drug interaction trial in healthy volunteers, a single 160 mg oral dose of XTANDI was administered alone or after multiple oral doses of itraconazole (strong CYP3A4 inhibitor). Itraconazole increased the AUC<span class="Sub">0-inf</span> of enzalutamide plus N-desmethyl enzalutamide by 1.3-fold with no effect on C<span class="Sub">max</span>. The results are summarized in Figure 1 <span class="Italics">[see <a href="#i4i_dosage_admin_id_6b2ad128-3683-4af7-aa7f-f56e6d0c6e30">Dosage and Administration</a> (<a href="#i4i_section_id_67ff910f-5662-4741-8c5a-08db7cef628b">2.2</a>) and <a href="#i4i_interactions_id_95e7e5ea-8a64-4b94-be6e-b07a80ef3c01">Drug Interactions</a> (<a href="#i4i_section_id_06eda248-5f46-43b7-8ed5-426f909644dc">7.2</a>)].</span></p>
<p>The effects of CYP2C8 and CYP3A4 inducers on the exposure of XTANDI have not been evaluated <span class="Italics">in vivo</span>. <br><br><span class="Bold">Figure 1. Effects of Other Drugs and Intrinsic/Extrinsic Factors on XTANDI</span></p>
<div class="Figure">
<a name="id1601364226"></a><img alt="Figure 1. Effects of Other Drugs and Intrinsic/Extrinsic Factors on XTANDI" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf&amp;name=d16edd51-c6e1-4c01-9be2-b40855e386eb-02.jpg">
</div>
<p><span class="Sup">#</span>PK parameters (C<span class="Sub">max</span> and AUC<span class="Sub">0-inf</span>) are for enzalutamide plus N-desmethyl enzalutamide, except in the food-effect trial, where they are for enzalutamide alone. <br>*See <a href="#i4i_dosage_admin_id_6b2ad128-3683-4af7-aa7f-f56e6d0c6e30">Dosage and Administration</a> (<a href="#i4i_section_id_67ff910f-5662-4741-8c5a-08db7cef628b">2.2</a>).<br><br><br><span class="Underline">Effect of XTANDI on Other Drugs:</span><br>In an <span class="Italics">in vivo</span> phenotypic cocktail drug-drug interaction trial in patients with metastatic CRPC, a single oral dose of the CYP probe substrate cocktail (for CYP2C8, CYP2C9, CYP2C19, and CYP3A4) was administered before and concomitantly with XTANDI (following at least 55 days of dosing at 160 mg daily). The results are summarized in Figure 2. Results showed that <span class="Italics">in vivo</span>, at steady state, XTANDI is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer <span class="Italics">[see <a href="#i4i_interactions_id_95e7e5ea-8a64-4b94-be6e-b07a80ef3c01">Drug Interactions</a> (<a href="#i4i_section_id_4166cda9-55e6-4c73-a1de-da77f29e3fc0">7.3</a>)]</span>. XTANDI did not cause clinically meaningful changes in exposure to the CYP2C8 substrate.</p>
<p><br><span class="Bold">Figure 2.  Effect of XTANDI on Other Drugs</span></p>
<div class="Figure">
<a name="id669460831"></a><img alt="Figure 2.  Effect of XTANDI on Other Drugs" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf&amp;name=image-01.jpg">
</div>
<p>*See <a href="#i4i_interactions_id_95e7e5ea-8a64-4b94-be6e-b07a80ef3c01">Drug Interactions</a> (<a href="#i4i_section_id_4166cda9-55e6-4c73-a1de-da77f29e3fc0">7.3</a>).<br><br><br><span class="Italics">In vitro</span>, enzalutamide, N-desmethyl enzalutamide, and the major inactive carboxylic acid metabolite caused direct inhibition of multiple CYP enzymes including CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5; however, subsequent clinical data showed that XTANDI is an inducer of CYP2C9, CYP2C19, and CYP3A4 and had no clinically meaningful effect on CYP2C8 (see Figure 2). <span class="Italics">In vitro</span>, enzalutamide caused time-dependent inhibition of CYP1A2. </p>
<p><span class="Italics">In vitro</span> studies showed that enzalutamide induces CYP2B6 and CYP3A4 and does not induce CYP1A2 at therapeutically relevant concentrations.</p>
<p><span class="Italics">In vitro</span>, enzalutamide, N-desmethyl enzalutamide, and the major inactive carboxylic acid metabolite are not substrates for human P-glycoprotein. <span class="Italics">In vitro</span>, enzalutamide and N-desmethyl enzalutamide are inhibitors of human P-glycoprotein, while the major inactive carboxylic acid metabolite is not.</p>
<p><span class="Italics">In vitro</span>, enzalutamide and N-desmethyl enzalutamide do not appear to be substrates of human breast cancer resistance protein (BCRP); however, enzalutamide and N-desmethyl enzalutamide are inhibitors of human BCRP at clinically relevant concentrations.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ef91768-6fd5-4e84-bd50-2c274520277f"></a><a name="section-11.3"></a><p></p>
<h2>12.6 Cardiac Electrophysiology</h2>
<p class="First">The effect of enzalutamide 160 mg/day at steady state on the QTc interval was evaluated in 796 patients with metastatic CRPC.  No large difference (i.e., greater than 20 ms) was observed between the mean QT interval change from baseline in patients treated with XTANDI and that in patients treated with placebo, based on the Fridericia correction method. However, small increases in the mean QTc interval (i.e., less than 10 ms) due to enzalutamide cannot be excluded due to limitations of the study design.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_e375862d-29d5-4b50-b500-2c91270ed958"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_a495a802-bee0-43e8-bd52-c3ee6773e70b"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been conducted to evaluate the carcinogenic potential of enzalutamide. </p>
<p>Enzalutamide did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in either the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> thymidine kinase (Tk) gene mutation assay or the <span class="Italics">in vivo</span> mouse micronucleus assay. </p>
<p>Based on nonclinical findings in repeat-dose toxicology studies, which were consistent with the pharmacological activity of enzalutamide, male fertility may be impaired by treatment with XTANDI. In a 26-week study in rats, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the prostate and seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> was observed at ≥ 30 mg/kg/day (equal to the human exposure based on AUC). In 4-, 13-, and 39-week studies in dogs, hypospermatogenesis and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the prostate and epididymides were observed at ≥ 4 mg/kg/day (0.3 times the human exposure based on AUC). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_c491781d-a64e-4591-ad31-7c4c4f90e577"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy and safety of XTANDI in patients with metastatic CRPC were demonstrated in two randomized, placebo-controlled, multicenter phase 3 clinical trials.  All patients continued on GnRH therapy or had prior bilateral orchiectomy. Patients were allowed, but not required, to continue or initiate glucocorticoids. </p>
<p><span class="Bold">Study 1:  Metastatic Castration-Resistant Prostate Cancer Following Chemotherapy</span><br>A total of 1199 patients who had received prior docetaxel-based chemotherapy were randomized 2:1 to receive either XTANDI orally at a dose of 160 mg once daily (N=800) or placebo orally once daily (N=399). Study treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression), initiation of new systemic antineoplastic treatment, unacceptable toxicity, or withdrawal. Patients with a previous history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, taking medicines known to decrease the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, or with other risk factors for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> were not eligible <span class="Italics">[see <a href="#i4i_warnings_precautions_id_f3fadd5f-4ed3-4b88-9a17-c83dfcde308d">Warnings and Precautions</a> (<a href="#i4i_section_id_2353d0ee-3120-4e4e-aef8-99f54b115f59">5.1</a>)]</span>.</p>
<p>The following patient demographics and baseline disease characteristics were balanced between the treatment arms. The median age was 69 years (range 41-92) and the racial distribution was 92.7% Caucasian, 3.9% Black, 1.1% Asian, and 2.1% Other. Ninety-two percent of patients had an ECOG performance status score of 0-1 and 28% had a mean Brief <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Inventory score of ≥ 4. Ninety-one percent of patients had <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> in bone and 23% had visceral involvement in the lung and/or liver. Fifty-nine percent of patients had radiographic evidence of disease progression and 41% had PSA-only progression on study entry. All patients had received prior docetaxel-based therapy and 24% had received two cytotoxic chemotherapy regimens. During the trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids. </p>
<p>A statistically significant improvement in overall survival was demonstrated at the pre-specified interim analysis at the time of 520 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in patients on the XTANDI arm compared to patients on the placebo arm (<a href="#_Ref381867191">Table 3</a> and Figure 3). </p>
<a name="_Ref381867191"></a><table width="100%">
<caption><span>Table 3. Overall Survival of Patients Treated with Either XTANDI or Placebo in Study 1</span></caption>
<col width="42%">
<col width="31%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">XTANDI</span></p>
<p><span class="Bold">N = 800</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo </span></p>
<p><span class="Bold">N = 399</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> (%) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">308 (38.5%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">212 (53.1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Median Survival, months (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">18.4 (17.3, NR) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13.6 (11.3, 15.8) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">P-value<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">&lt; 0.0001 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Hazard Ratio (95% CI)<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">0.63 (0.53, 0.75) </p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a)</span> P-value is derived from a log-rank test stratified by baseline ECOG performance status score (0-1 vs. 2) and mean baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score (BPI-SF score &lt; 4 vs. ≥ 4)<br><span class="Sup">b)</span> Hazard Ratio is derived from a stratified proportional hazards model. Hazard ratio &lt;1 favors XTANDI <br>NR denotes “not reached?.</p>
<p><span class="Bold">Figure 3. Kaplan-Meier Overall Survival Curves in Study 1</span></p>
<div class="Figure">
<a name="id1513959544"></a><img alt="Figure 3. Kaplan-Meier Overall Survival Curves (Intent-to-Treat Analysis)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf&amp;name=d16edd51-c6e1-4c01-9be2-b40855e386eb-04.jpg">
</div>
<p><span class="Bold">Study 2: Chemotherapy-naive Metastatic Castration-Resistant Prostate Cancer</span><br>In Study 2, 1717 chemotherapy-naive patients were randomized 1:1 to receive either XTANDI orally at a dose of 160 mg once daily (N=872) or placebo orally once daily (N=845). Patients with visceral <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, patients with a history of mild to moderate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (NYHA class I or II), and patients taking medications associated with lowering the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold were allowed. Patients with a previous history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or a condition that might predispose to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from prostate cancer were excluded. Study treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal. Overall survival and radiographic progression-free survival (rPFS) were assessed. Radiographic progression was assessed with the use of sequential imaging and was defined by bone scan identification of 2 or more new bone lesions with confirmation (Prostate Cancer Clinical Trials Working Group 2 criteria) and/or Response Evaluation Criteria in <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span> (RECIST v 1.1) criteria for progression of soft tissue lesions. The primary analysis of rPFS utilized centrally reviewed radiographic assessment of progression. </p>
<p>Patient demographics and baseline disease characteristics were balanced between the treatment arms at entry. The median age was 71 years (range 42-93) and the racial distribution was 77% Caucasian, 10% Asian, 2% Black and 11% Other. The ECOG performance status score was 0 for 68% of patients, and 1 for 32% of patients. Baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> assessment was 0-1 (asymptomatic) in 67% of patients, and 2-3 (mildly symptomatic) in 32% of patients as defined by the Brief <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Inventory Short Form (worst <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> over past 24 hours at study entry). Fifty-four percent of patients had radiographic evidence of disease progression and 43% had PSA-only progression. Twelve percent of patients had visceral (lung and/or liver) disease involvement. During the study, 27% of patients on the XTANDI arm and 30% of patients on the placebo arm received glucocorticoids for varying reasons.  </p>
<p>A statistically significant improvement in overall survival was demonstrated at the pre-specified interim analysis, conducted after 540 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in patients treated with XTANDI compared to those treated with placebo (<a href="#Table4">Table 4</a>). Forty percent of XTANDI-treated and 70% of placebo-treated patients received subsequent therapies for metastatic CRPC that may prolong overall survival. An updated survival analysis was conducted when 784 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were observed. The median follow-up time was 31 months. Results from this analysis were consistent with those from the pre-specified interim analysis (Table 4, Figure 4). At the updated analysis, 52% of XTANDI-treated and 81% of placebo-treated patients had received subsequent therapies that may prolong overall survival in metastatic CRPC. XTANDI was used as a subsequent therapy in 2% of XTANDI-treated patients and 29% of placebo-treated patients.</p>
<a name="Table4"></a><table width="463.5pt">
<caption><span>Table 4. Overall Survival of Patients Treated with Either XTANDI or Placebo in Study 2</span></caption>
<col width="44%">
<col width="26%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">XTANDI </span></p>
<p><span class="Bold">N = 872</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo </span></p>
<p><span class="Bold">N = 845</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Pre-specified Interim Analysis</span><span class="Sup">a</span></p></td>
<td class="Botrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd>Number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> (%) </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">241 (28%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">299 (35%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>Median Survival, months (95% CI)</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">32.4 (30.1, NR) </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30.2 (28.0, NR) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>P-value<span class="Sup">b</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First">&lt; 0.0001 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt> </dt>
<dd>Hazard Ratio (95% CI)<span class="Sup">c</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First">0.71 (0.60, 0.84) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Updated Survival Analysis</span><span class="Sup">d</span></p></td>
<td class="Botrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd>Number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> (%)</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">368 (42%)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">416 (49%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd>Median Survival, months (95% CI)</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">35.3 (32.2, NR)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">31.3 (28.8, 34.2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><dl>
<dt> </dt>
<dd>Hazard Ratio (95% CI)<span class="Sup">c</span>
</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First">0.77 (0.67, 0.88)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a)</span> The data cutoff date is 16 Sep 2013 <br><span class="Sup">b) </span>P-value is derived from an unstratified log-rank test. <br><span class="Sup">c)</span> Hazard ratio is derived from an unstratified proportional hazards model.  Hazard ratio &lt; 1 favors XTANDI.<br><span class="Sup">d)</span> The data cutoff date is 1 Jun 2014. The planned number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> for the final overall survival analysis was ≥765.<br>NR denotes “not reached?.</p>
<p><span class="Bold">Figure 4. Kaplan-Meier Overall Survival Curves in Study 2</span></p>
<div class="Figure">
<a name="id-1010214961"></a><img alt="Figure 4. Kaplan-Meier Overall Survival Curves in Study 2 (Intent-to-Treat Analysis)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf&amp;name=image-03.jpg">
</div>
<p>A statistically significant improvement in rPFS was demonstrated in patients treated with XTANDI compared to patients treated with placebo (<a href="#_RefTable5">Table 5</a>, Figure 5). </p>
<a name="_RefTable5"></a><table width="100%">
<caption><span>Table 5. Radiographic Progression-free Survival of Patients Treated with Either XTANDI or Placebo in Study 2 </span></caption>
<col width="42%">
<col width="31%">
<col width="27%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">XTANDI</span></p>
<p><span class="Bold">N = 832</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo </span></p>
<p><span class="Bold">N = 801</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Number of Progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> (%) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">118 (14%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">320 (40%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Median rPFS (months) (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">NR (13.8, NR) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.7 (3.6, 4.6) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">P-value<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">&lt; 0.0001 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Hazard Ratio (95% CI)<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">0.17 (0.14, 0.21) </p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a)</span> P-value is derived from an unstratified log-rank test <br><span class="Sup">b)</span> Hazard Ratio is derived from an unstratified proportional hazards model. Hazard ratio &lt;1 favors XTANDI<br>NR denotes “not reached?.<br>Note: As of the cutoff date for the rPFS analysis, 1633 patients had been randomized.<br><br><span class="Bold">Figure 5. Kaplan-Meier Curves for Duration of Radiographic Progression-free Survival in Study 2</span></p>
<div class="Figure">
<a name="id291020722"></a><img alt="Figure 5. Kaplan-Meier Curves for Duration of Radiographic Progression-free Survival in Study 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf&amp;name=d16edd51-c6e1-4c01-9be2-b40855e386eb-06.jpg">
</div>
<p>Time to initiation of cytotoxic chemotherapy was prolonged after XTANDI treatment, with a median of 28.0 months for patients on the XTANDI arm versus a median of 10.8 months for patients on the placebo arm [HR=0.35 (95% CI: 0.30, 0.40), p &lt; 0.0001)]. </p>
<p>The median time to first skeletal‑related event was 31.1 months for patients on the XTANDI arm versus 31.3 months for patients on the placebo arm [HR = 0.72 (95% CI: 0.61, 0.84), p &lt; 0.0001].  A skeletal‑related event was defined as radiation therapy or surgery to bone for prostate cancer, pathologic bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">spinal cord compression</span>, or change of antineoplastic therapy to treat <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_8208369e-b01b-434d-bebb-1551eca622e8"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<dl>
<dt>•</dt>
<dd>XTANDI (enzalutamide) 40 mg capsules are supplied as white to off-white oblong soft gelatin capsules imprinted in black ink with ENZ. XTANDI capsules are available in the following package sizes:<dl>
<dt>•</dt>
<dd>Bottles of 120 capsules (NDC 0469-0125-99) </dd>
</dl>
</dd>
</dl>
<p class="First">Recommended storage: Store XTANDI capsules at 20°C to 25°C (68°F to 77°F) in a dry place and keep the container tightly closed. Excursions permitted from 15°C to 30°C (59°F to 86°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_67524491-bb05-45b8-8a68-82059d1cb0ff"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">See <a href="#ID_6dcbfc8a-5f78-4f73-9f7f-e9f4d03c6e2e">FDA-approved patient labeling (PATIENT INFORMATION)</a></span>.</p>
<dl>
<dt>•</dt>
<dd>Instruct patients to take their dose at the same time each day (once daily). XTANDI can be taken with or without food. Each capsule should be swallowed whole.  Do not chew, dissolve, or open the capsules.</dd>
<dt>•</dt>
<dd>Inform patients receiving GnRH therapy that they need to maintain this treatment during the course of treatment with XTANDI.</dd>
<dt>•</dt>
<dd>Inform patients that XTANDI has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. Discuss conditions that may predispose to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and medications that may lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold.  Advise patients of the risk of engaging in any activity where sudden <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> could cause serious harm to themselves or others. Inform patients to contact their physician right away if they have <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>.</dd>
<dt>•</dt>
<dd>Inform patients to contact their physician right away if they experience rapidly worsening symptoms possibly indicative of PRES such as <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, decreased alertness, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, reduced eyesight, or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</dd>
<dt>•</dt>
<dd>Inform patients that they should not interrupt, modify the dose, or stop XTANDI without first consulting their physician. Inform patients that if they miss a dose, then they should take it as soon as they remember. If they forget to take the dose for the whole day, then they should take their normal dose the next day. They should not take more than their prescribed dose per day.</dd>
<dt>•</dt>
<dd>Apprise patients of the most common side effects associated with XTANDI: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. Direct the patient to a complete list of adverse drug reactions in <a href="#ID_6dcbfc8a-5f78-4f73-9f7f-e9f4d03c6e2e">PATIENT INFORMATION</a>. </dd>
<dt>•</dt>
<dd>Inform patients that XTANDI may cause <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> and <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>-related injuries, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. </dd>
<dt>•</dt>
<dd>Inform patients that XTANDI can be harmful to a developing fetus. Patients should also be informed that they should use a condom if having sex with a pregnant woman. A condom and another effective method of birth control should be used if the patient is having sex with a woman of child-bearing potential. These measures are required during and for three months after treatment with XTANDI.</dd>
</dl>
<p><span class="Bold">Manufactured by:</span> Catalent Pharma Solutions, LLC, St. Petersburg, FL 33716</p>
<p><span class="Bold">Manufactured for and Distributed by: </span>Astellas Pharma US, Inc., Northbrook, IL 60062</p>
<p><span class="Bold">Marketed by:</span><br>Astellas Pharma US, Inc., Northbrook, IL 60062<br>Medivation, Inc., San Francisco, CA 94105<br><br>14L082-XTA<br><br><span class="Bold">Rx Only</span><br><span class="Bold">© 2015 Astellas Pharma US, Inc. </span></p>
<p><span class="Bold">XTANDI<span class="Sup">®</span> is a registered trademark of Astellas Pharma Inc.</span> </p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_6dcbfc8a-5f78-4f73-9f7f-e9f4d03c6e2e"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">XTANDI<span class="Sup">®</span> (ex TAN dee)<br>(enzalutamide) <br>capsules</span></p>
<p><span class="Bold">What is XTANDI?</span></p>
<p>XTANDI is a prescription medicine used to treat men with prostate cancer that no longer responds to a medical or surgical treatment that lowers testosterone and that has spread to other parts of the body. </p>
<p>It is not known if XTANDI is safe and effective in children.</p>
<p><span class="Bold">Who should not take XTANDI?</span></p>
<p>XTANDI is not for use in women.</p>
<p>Do not take XTANDI if you are pregnant or may become pregnant. XTANDI can harm your unborn baby.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking XTANDI? </span></p>
<p><span class="Bold">Before you take XTANDI, tell your healthcare provider if you:</span></p>
<dl>
<dt>•</dt>
<dd>have a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, brain injury, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumors</span></dd>
<dt>•</dt>
<dd>have any other medical conditions</dd>
<dt>•</dt>
<dd>have a partner who is pregnant or may become pregnant. Men who are sexually active with a pregnant woman must use a condom during and for 3 months after treatment with XTANDI. If your sexual partner may become pregnant, a condom and another form of effective birth control must be used during and for 3 months after treatment. Talk with your healthcare provider if you have questions about birth control. See <span class="Bold">“Who should not take XTANDI??</span>
</dd>
</dl>
<p>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. XTANDI may affect the way other medicines work, and other medicines may affect how XTANDI works.</p>
<p>You should not start or stop any medicine before you talk with the healthcare provider that prescribed XTANDI.</p>
<p>Know the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take XTANDI?</span></p>
<dl>
<dt>•</dt>
<dd>Take XTANDI exactly as your healthcare provider tells you.  </dd>
<dt>•</dt>
<dd>Take your prescribed dose of XTANDI one time a day, at the same time each day.</dd>
<dt>•</dt>
<dd>Your healthcare provider may change your dose if needed. </dd>
<dt>•</dt>
<dd>Do not change or stop taking your prescribed dose of XTANDI without talking with your healthcare provider first.</dd>
<dt>•</dt>
<dd>XTANDI can be taken with or without food.</dd>
<dt>•</dt>
<dd>Swallow XTANDI capsules whole.  Do not chew, dissolve, or open the capsules.</dd>
<dt>•</dt>
<dd>If you miss a dose of XTANDI, take your prescribed dose as soon as you remember that day.  If you miss your daily dose, take your prescribed dose at your regular time the next day.  Do not take more than your prescribed dose of XTANDI in one day. </dd>
</dl>
<p>If you take too much XTANDI, call your healthcare provider or go to the nearest emergency room right away. You may have an increased risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> if you take too much XTANDI.</p>
<p><span class="Bold">What are the possible side effects of XTANDI?</span></p>
<p><span class="Bold">XTANDI may cause serious side effects including:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>. </span>If you take XTANDI you may be at risk of having a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. You should avoid activities where a sudden <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> could cause serious harm to yourself or others. Tell your healthcare provider right away if you have <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. Your healthcare provider will stop XTANDI if you have a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> during treatment.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Posterior Reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> Syndrome (PRES).</span> If you take XTANDI you may be at risk of developing a condition involving the brain called PRES. Tell your healthcare provider right away if you have a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or quickly worsening symptoms such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, decreased alertness, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>,  reduced eyesight, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> or other visual problems. Your healthcare provider will do a test to check for PRES. Your healthcare provider will stop XTANDI if you develop PRES. </dd>
<dt> </dt>
<dd><span class="Bold">The most common side effects of XTANDI include: </span></dd>
</dl>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless"><tr class="First Last">
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or feeling more tired than usual</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your hands, arms, legs, or feet</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></dd>
<dt>•</dt>
<dd>muscle and <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>•</dt>
<dd>high blood pressure</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>•</dt>
<dd>a feeling that you or things around you are moving or spinning (<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>)</dd>
</dl></td>
</tr></tbody>
</table>
<p>XTANDI may cause <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> and injuries from <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. Tell your healthcare provider if you have signs or symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or if you <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>. </p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects of XTANDI. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store XTANDI?</span></p>
<dl>
<dt>•</dt>
<dd>Store XTANDI between 68°F to 77°F (20°C to 25°C). </dd>
<dt>•</dt>
<dd>Keep XTANDI capsules dry and in a tightly closed container.</dd>
</dl>
<p><span class="Bold">Keep XTANDI and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about XTANDI.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use XTANDI for a condition for which it was not prescribed. Do not give XTANDI to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>This Patient Information leaflet summarizes the most important information about XTANDI. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about XTANDI that is written for health professionals.</p>
<p>For more information go to www.Xtandi.com or call 1-800-727-7003.</p>
<p><span class="Bold">What are the ingredients in XTANDI?</span></p>
<p><span class="Bold">Active ingredient:</span> enzalutamide</p>
<p><span class="Bold">Inactive ingredients:</span> caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, black iron oxide</p>
<p> </p>
<p>Manufactured by: Catalent Pharma Solutions, LLC, St. Petersburg, FL 33716</p>
<p>Marketed by: Astellas Pharma US, Inc., Northbrook, IL 60062  Medivation Inc., San Francisco, CA 94105</p>
<p>14L082-XTA</p>
<p>© 2015 Astellas Pharma US, Inc. </p>
<p>XTANDI<span class="Sup">®</span> is a registered trademark of Astellas Pharma Inc.</p>
<p> </p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.       Revised: 08/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_78bba3f5-bf88-465d-89db-c1c07f4f8385"></a><a name="section-17"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id1230"></a><img alt="Bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf&amp;name=d16edd51-c6e1-4c01-9be2-b40855e386eb-08.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XTANDI 		
					</strong><br><span class="contentTableReg">enzalutamide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0469-0125</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENZALUTAMIDE</strong> (ENZALUTAMIDE) </td>
<td class="formItem">ENZALUTAMIDE</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ENZ</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0469-0125-99</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">120  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203415</td>
<td class="formItem">08/31/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Astellas Pharma US, Inc.
							(605764828)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b4ed567d-8e9e-418d-87cd-6f5be8d1d204</div>
<div>Set id: b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf</div>
<div>Version: 6</div>
<div>Effective Time: 20150803</div>
</div>
</div> <div class="DistributorName">Astellas Pharma US, Inc.</div></p>
</body></html>
